Sugi Predict

Sugi Predict / Compounds / SCHEMBL5065304

SCHEMBL5065304

SCHEMBL5065304

CSc1ncc2cc(-c3ccc(F)c(N)c3)c(=O)[nH]c2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIK2 Q9H0K1 1/20 0.36
▸ BRD4 O60885 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ HSD17B10 Q99714 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ AKT1 P31749 3/20 0.33
▸ AKT2 P31751 3/20 0.33
▸ CYP2C9 P11712 2/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ CYP1A1 P04798 1/20 0.33
▸ CHEK1 O14757 1/20 0.33
▸ MAPT P10636 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21990251 0.82 SIK2 (0.43) SIK2MEN1KMT2ANPC1RAB9A
SCHEMBL20564939 0.79 MEN1 (0.51) SIK2MEN1KMT2AAKT1AKT2
SCHEMBL4180912 0.79 MEN1 (0.40) SIK2MEN1KMT2ANPC1RAB9A
SCHEMBL22718993 0.78 LIG1 (0.42) SIK2MEN1KMT2ANPC1RAB9A
SCHEMBL29535783 0.78 LIG1 (0.42) SIK2MEN1KMT2ANPC1RAB9A
SCHEMBL6073545 0.77 HPGD (0.40) MEN1KMT2ANPC1TP53RAB9A
SCHEMBL4283199 0.76 FGFR1 (0.45) SIK2BRD4HSD17B10ALDH1A1CYP1A2
SCHEMBL22538190 0.75 SRC (0.41) SIK2BRD4HSD17B10NPC1TP53
SCHEMBL4566592 0.75 PIK3CA (0.42) BRD4HSD17B10NPC1TP53PKM
SCHEMBL23638430 0.75 PRKCI (0.48) SIK2MEN1KMT2APDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 — — US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 — — US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 SIK2 596/4885BRD4 1320/4885MEN1 880/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 SIK2 596/4885BRD4 1320/4885MEN1 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.